95 related articles for article (PubMed ID: 2159428)
41. Epidemiology of borderline ovarian tumors.
Harlow BL; Weiss NS; Lofton S
J Natl Cancer Inst; 1987 Jan; 78(1):71-4. PubMed ID: 3025504
[TBL] [Abstract][Full Text] [Related]
42. Should All Cases of High-Grade Serous Ovarian, Tubal, and Primary Peritoneal Carcinomas Be Reclassified as Tubo-Ovarian Serous Carcinoma?
Moss EL; Evans T; Pearmain P; Askew S; Singh K; Chan KK; Ganesan R; Hirschowitz L
Int J Gynecol Cancer; 2015 Sep; 25(7):1201-7. PubMed ID: 26035124
[TBL] [Abstract][Full Text] [Related]
43. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
Silva EG; Gershenson DM; Malpica A; Deavers M
Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
[TBL] [Abstract][Full Text] [Related]
44. Impact of prognostic factors on survival rates in patients with ovarian carcinoma.
Arikan SK; Kasap B; Yetimalar H; Yildiz A; Sakarya DK; Tatar S
Asian Pac J Cancer Prev; 2014; 15(15):6087-94. PubMed ID: 25124578
[TBL] [Abstract][Full Text] [Related]
45. Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy.
Bamias A; Psaltopoulou T; Sotiropoulou M; Haidopoulos D; Lianos E; Bournakis E; Papadimitriou C; Rodolakis A; Vlahos G; Dimopoulos MA
Cancer; 2010 Mar; 116(6):1462-8. PubMed ID: 20108307
[TBL] [Abstract][Full Text] [Related]
46. Ovarian surface epithelial neoplasms in the pediatric population: incidence, histologic subtype, and natural history.
Hazard FK; Longacre TA
Am J Surg Pathol; 2013 Apr; 37(4):548-53. PubMed ID: 23388124
[TBL] [Abstract][Full Text] [Related]
47. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.
Chan JK; Tian C; Monk BJ; Herzog T; Kapp DS; Bell J; Young RC;
Cancer; 2008 May; 112(10):2202-10. PubMed ID: 18348296
[TBL] [Abstract][Full Text] [Related]
48. Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma.
Sutton GP; Stehman FB; Einhorn LH; Roth LM; Blessing JA; Ehrlich CE
J Clin Oncol; 1989 Feb; 7(2):223-9. PubMed ID: 2915238
[TBL] [Abstract][Full Text] [Related]
49. Restaging and Survival Analysis of 4036 Ovarian Cancer Patients According to the 2013 FIGO Classification for Ovarian, Fallopian Tube, and Primary Peritoneal Cancer.
Rosendahl M; Høgdall CK; Mosgaard BJ
Int J Gynecol Cancer; 2016 May; 26(4):680-7. PubMed ID: 26937751
[TBL] [Abstract][Full Text] [Related]
50. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
[TBL] [Abstract][Full Text] [Related]
51. The Impact of Percent Reduction in CA-125 Levels on Prediction of the Extent of Interval Cytoreduction and Outcome in Patients With Advanced-Stage Cancer of Müllerian Origin Treated With Neoadjuvant Chemotherapy.
Mahdi H; Maurer KA; Nutter B; Rose PG
Int J Gynecol Cancer; 2015 Jun; 25(5):823-9. PubMed ID: 25828750
[TBL] [Abstract][Full Text] [Related]
52. Natural history and outcome of mucinous carcinoma of the ovary.
Schiavone MB; Herzog TJ; Lewin SN; Deutsch I; Sun X; Burke WM; Wright JD
Am J Obstet Gynecol; 2011 Nov; 205(5):480.e1-8. PubMed ID: 21861962
[TBL] [Abstract][Full Text] [Related]
53. Clinicopathological characteristics of mucinous adenocarcinoma of the ovary.
Shimada M; Kigawa J; Ohishi Y; Yasuda M; Suzuki M; Hiura M; Nishimura R; Tabata T; Sugiyama T; Kaku T
Gynecol Oncol; 2009 Jun; 113(3):331-4. PubMed ID: 19275957
[TBL] [Abstract][Full Text] [Related]
54. [Clinicopathologic analysis of ovarian serous and mucinous borderline tumors].
Zhong C; Yu X; Zhang J; Wei B; Luo B; Sun L; Zhang N; Fu Q
Zhonghua Bing Li Xue Za Zhi; 2001 Aug; 30(4):253-5. PubMed ID: 11758211
[TBL] [Abstract][Full Text] [Related]
55. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
[TBL] [Abstract][Full Text] [Related]
56. Survival Benefit of Adjuvant Radiotherapy: An Analysis of Low-Stage Invasive Ovarian Mucinous Carcinomas.
Kumar A; Le N; Gilks CB; Santos JL; Wong F; Swenerton K; Hoskins PJ; McAlpine JN; Tinker AV
Int J Gynecol Cancer; 2017 Nov; 27(9):1819-1825. PubMed ID: 28930809
[TBL] [Abstract][Full Text] [Related]
57. [Combined pegylated liposomal doxorubicin and carboplatin in the treatment of recurrent epithelial ovarian cancer].
Zheng H; Gao YN; Jiang GQ; Gao M; Wang W; Yan X
Zhonghua Fu Chan Ke Za Zhi; 2008 Nov; 43(11):839-42. PubMed ID: 19087568
[TBL] [Abstract][Full Text] [Related]
58. The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma.
Piver MS; Lele SB; Marchetti DL; Baker TR; Tsukada Y; Emrich LJ
J Clin Oncol; 1988 Jun; 6(6):983-9. PubMed ID: 3373267
[TBL] [Abstract][Full Text] [Related]
59. Survival of Patients With Mucinous Ovarian Carcinoma and Ovarian Metastases: A Population-Based Cancer Registry Study.
Simons M; Ezendam N; Bulten J; Nagtegaal I; Massuger L
Int J Gynecol Cancer; 2015 Sep; 25(7):1208-15. PubMed ID: 25978291
[TBL] [Abstract][Full Text] [Related]
60. Ovarian cancer chemotherapy: carboplatin as standard.
Tattersall MN
Lancet; 2002 Aug; 360(9332):500-1. PubMed ID: 12241648
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
